Margarida Azevedo, MSc,  —

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Articles by Margarida Azevedo

Researchers Identify Promising Targets in Molecular Pathway Involved in Sporadic Parkinson’s Disease

Researchers at the Buck Institute for Research on Aging have learned that oxidative stress, a main driver in sporadic Parkinson’s Disease, affects the parkin protein – essential to clear damaged proteins and mitochondria in cells – in the same manner that genetic mutations do. The findings help researchers better understand sporadic PD. The molecular dysfunction…

Parkinson’s Patient, After Nerve Cell Transplant, Showed ‘Major’ Benefits for Nearly 25 Years

Lund University researchers followed a Parkinson’s disease patient who had undergone neuronal transplantation, and reported the patient experienced long-term “major clinical benefits,” including the restoration of normal dopamine function. Importantly, transplant-derived cell reinnervation was evident for almost 25 years, although the disease again began to progress some 14 years after transplantation. The study, “…

Neuronal Changes Seen in Parkinson’s Mouse Model Well Before Disease Symptoms

University of Texas Health Science Center researchers have identified physiologic changes in dopamine neurons in a key animal model of Parkinson’s known to display disease symptoms, the MitoPark mouse model. The dopamine changes in the mice, however, clearly came before any symptoms appeared — findings that may lead to earlier identification of  Parkinson’s in people,…

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums